New study of ExThera Medical’s Seraph(TM) Affinity Apheresis Device Demonstrates Its Potential for Reducing the High Death Rate from Sepsis, a Top-10 Cause of Death in the U.S.

BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical Corporation announced today that a new study of its breakthrough Seraph™ (Selective Removal by Apheresis) affinity therapy device demonstrates its potential as a treatment for patients suffering from Staphylococcus aureus- and/or Methicillin-Resistant S. aureus (MRSA)-induced sepsis.